Montanaro Asset Management Ltd Trims Stock Position in Masimo Co. (NASDAQ:MASI)

Montanaro Asset Management Ltd cut its stake in Masimo Co. (NASDAQ:MASI - Free Report) by 16.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 46,500 shares of the medical equipment provider's stock after selling 9,200 shares during the quarter. Masimo comprises approximately 1.6% of Montanaro Asset Management Ltd's holdings, making the stock its 28th largest holding. Montanaro Asset Management Ltd owned approximately 0.09% of Masimo worth $7,686,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of MASI. Algert Global LLC boosted its position in shares of Masimo by 37.9% during the third quarter. Algert Global LLC now owns 19,139 shares of the medical equipment provider's stock valued at $2,552,000 after buying an additional 5,260 shares during the period. Harvest Fund Management Co. Ltd purchased a new position in Masimo during the 3rd quarter valued at $118,000. FMR LLC grew its position in Masimo by 41.2% in the 3rd quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider's stock valued at $900,860,000 after acquiring an additional 1,970,883 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Masimo by 76.4% in the third quarter. BNP Paribas Financial Markets now owns 19,982 shares of the medical equipment provider's stock worth $2,664,000 after purchasing an additional 8,656 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Masimo during the third quarter worth $4,120,000. 85.96% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Activity at Masimo

In related news, COO Bilal Muhsin sold 30,000 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the completion of the transaction, the chief operating officer now owns 24,172 shares in the company, valued at $4,048,568.28. This trade represents a 55.38 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Craig B. Reynolds sold 2,053 shares of the business's stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the sale, the director now owns 16,581 shares in the company, valued at approximately $2,754,601.53. The trade was a 11.02 % decrease in their position. The disclosure for this sale can be found here. 9.70% of the stock is currently owned by insiders.

Masimo Stock Down 0.3 %

MASI traded down $0.44 during trading on Monday, hitting $163.11. The stock had a trading volume of 101,371 shares, compared to its average volume of 638,369. The stock has a 50 day simple moving average of $174.79 and a two-hundred day simple moving average of $161.72. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. Masimo Co. has a twelve month low of $101.61 and a twelve month high of $194.88. The company has a market capitalization of $8.80 billion, a PE ratio of 112.49 and a beta of 1.04.

Masimo (NASDAQ:MASI - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm had revenue of $600.70 million during the quarter, compared to analysts' expectations of $593.35 million. On average, research analysts predict that Masimo Co. will post 4.1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MASI has been the topic of several recent analyst reports. Piper Sandler raised their price target on shares of Masimo from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Raymond James raised their target price on shares of Masimo from $170.00 to $194.00 and gave the stock an "outperform" rating in a research report on Friday, December 27th. Wells Fargo & Company boosted their price target on Masimo from $193.00 to $205.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Finally, Needham & Company LLC restated a "hold" rating on shares of Masimo in a report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $194.80.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.